CHMP backs basket of therapies

EMA's CHMP recommended marketing authorization of three new medicines Thursday and recommended label expansions for Revlimid lenalidomide from Celgene Corp. (NASDAQ:CELG) and Revolade eltrombopag from Novartis AG (NYSE:NVS; SIX:NOVN).

CHMP backed Empliciti elotuzumab from Bristol-Myers Squibb Co. (NYSE:BMY) and AbbVie Inc. (NYSE:ABBV) to treat multiple myeloma (MM) in combination with Revlimid and dexamethasone in patients that have received at least one prior therapy. FDA approved the humanized mAb targeting SLAM family member 7 ( SLAMF7; CS1) in November (see BioCentury Extra, Nov. 30, 2015). ...